Portal de Periódicos da CAPES

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas

2014; Nature Portfolio; Volume: 46; Issue: 7 Linguagem: Inglês

10.1038/ng.2995

1546-1718

Liwei Zhang, Lee H. Chen, Hong Wan, Rui Yang, Zhaohui Wang, Jie Feng, Shaohua Yang, Siân Jones, Sizhen Wang, Weixin Zhou, Huishan Zhu, Patrick Killela, Junting Zhang, Zhenhua Wu, Guilin Li, Shuyu Hao, Yu Wang, Joseph B Webb, Henry S. Friedman, Allan H. Friedman, Roger E. McLendon, Yiping He, Zachary J. Reitman, Darell D. Bigner, Hai Yan,

MicroRNA in disease regulation

Hai Yan, Zachary Reitman and colleagues report exome sequencing of resected tumor tissue from brainstem gliomas and thalamic gliomas and identify mutations in PPM1D in brainstem gliomas. Gliomas arising in the brainstem and thalamus are devastating tumors that are difficult to surgically resect. To determine the genetic and epigenetic landscape of these tumors, we performed exomic sequencing of 14 brainstem gliomas (BSGs) and 12 thalamic gliomas. We also performed targeted mutational analysis of an additional 24 such tumors and genome-wide methylation profiling of 45 gliomas. This study led to the discovery of tumor-specific mutations in PPM1D, encoding wild-type p53–induced protein phosphatase 1D (WIP1), in 37.5% of the BSGs that harbored hallmark H3F3A mutations encoding p.Lys27Met substitutions. PPM1D mutations were mutually exclusive with TP53 mutations in BSG and attenuated p53 activation in vitro. PPM1D mutations were truncating alterations in exon 6 that enhanced the ability of PPM1D to suppress the activation of the DNA damage response checkpoint protein CHK2. These results define PPM1D as a frequent target of somatic mutation and as a potential therapeutic target in brainstem gliomas.